YU22502A - Fibrinolitički aktivni polipeptid - Google Patents

Fibrinolitički aktivni polipeptid

Info

Publication number
YU22502A
YU22502A YU22502A YUP22502A YU22502A YU 22502 A YU22502 A YU 22502A YU 22502 A YU22502 A YU 22502A YU P22502 A YUP22502 A YU P22502A YU 22502 A YU22502 A YU 22502A
Authority
YU
Yugoslavia
Prior art keywords
fibrinolitically
active polypeptide
vivo
useful
called
Prior art date
Application number
YU22502A
Other languages
English (en)
Inventor
Thomas Charles Boone
Huimin Li
Michael Benjamin Mann
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Priority to YUP-2006/0033A priority Critical patent/RS20060033A/sr
Publication of YU22502A publication Critical patent/YU22502A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Opisan je fibrinolitički aktivan polipeptid metaloproteinaza (SEQ ID NO:1), njegova primena i postupci i materijali za njegovu proizvodnju rekombinantnom ekspresijom. MRFPSIFTAV LFAASSALAA PVNTTTEDET AOIPAEAVIG YSDLEGDFDV AVLPESNSTN NGLLPINTTI ASIAAKEEGV SLEKREAEAS SIILESGNVN DYEVVYPRKV TPVPRGAVOP KYEDAMOYEF KVNSEPVVLH LEKNKGLFSE DYSETHYSPD GREITTYPLG EDHCYYHGEI ENDADSTASI SACNGLKGHF KLOGEMYLIE PLELSDSEAH AVYKYENVEK EDEAPKMCGV TONWESYEPI KKAFOLNLTK RSFPQRYVQL VIVADHRMNT KYNGDSDKIR QWVHQIVNTI NEIYRPLNIQ FTLVGLEIWS NQDLITVTSV SHDTLASFGN WRETDLLRRQ RHDNAQLLTA IDFDGDTVGL AYVGGMCQLR HSTGVIQDHS AINLLVALTM AHELGHNLGM NHDGNQCHCG ANSCVMAAML SDQPSKLFSD CSKKDYQTFL TVNNPQCILN KP[A fibrinolytically active metalloproteinase polypeptide (called "novel acting thrombolytic") which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.
YU22502A 1999-10-01 2000-09-20 Fibrinolitički aktivni polipeptid YU22502A (sh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
YUP-2006/0033A RS20060033A (sr) 1999-10-01 2000-09-29 Fibrinolitički aktivan polipeptid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/411,329 US6261820B1 (en) 1999-10-01 1999-10-01 Fibronolytically active polypeptide

Publications (1)

Publication Number Publication Date
YU22502A true YU22502A (sh) 2005-07-19

Family

ID=23628486

Family Applications (2)

Application Number Title Priority Date Filing Date
YU22502A YU22502A (sh) 1999-10-01 2000-09-20 Fibrinolitički aktivni polipeptid
YU59604A YU59604A (sh) 1999-10-01 2000-09-20 Fibrinolitički aktivan polipeptid

Family Applications After (1)

Application Number Title Priority Date Filing Date
YU59604A YU59604A (sh) 1999-10-01 2000-09-20 Fibrinolitički aktivan polipeptid

Country Status (29)

Country Link
US (4) US6261820B1 (sh)
EP (2) EP1224298B1 (sh)
JP (1) JP2003511034A (sh)
KR (2) KR100700753B1 (sh)
CN (2) CN100357430C (sh)
AT (1) ATE292180T1 (sh)
AU (1) AU767827B2 (sh)
BG (1) BG106577A (sh)
BR (1) BR0014414A (sh)
CA (1) CA2386185A1 (sh)
CZ (1) CZ298502B6 (sh)
DE (1) DE60019147T2 (sh)
DK (1) DK1224298T3 (sh)
EA (2) EA006487B1 (sh)
ES (1) ES2240167T3 (sh)
HK (1) HK1049351B (sh)
HU (1) HUP0202650A3 (sh)
IL (1) IL148787A0 (sh)
MX (1) MXPA02003126A (sh)
NO (1) NO20021501L (sh)
NZ (1) NZ517951A (sh)
PL (1) PL355017A1 (sh)
PT (1) PT1224298E (sh)
RS (1) RS20060033A (sh)
SG (1) SG127720A1 (sh)
SK (1) SK4232002A3 (sh)
WO (1) WO2001025445A1 (sh)
YU (2) YU22502A (sh)
ZA (1) ZA200202206B (sh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US7033776B2 (en) 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
US6455269B1 (en) 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
US6523647B2 (en) * 2001-05-21 2003-02-25 Hydro Mobile Inc. Elevating platform assembly
AU2003215119B2 (en) * 2002-02-11 2008-11-20 Gold-T Tech, Inc. Method for preventing thrombus formation
US7016409B2 (en) * 2003-11-12 2006-03-21 Sony Corporation Apparatus and method for use in providing dynamic bit rate encoding
ES2239532B1 (es) * 2004-02-06 2006-11-01 Proyecto De Biomedicina Cima S.L. Metodo para evaluar el riesgo y la predisposicion a desarrollar una patologia relacionada con la presencia de autoanticuerpos frente a epcr.
US20070141625A1 (en) * 2005-02-03 2007-06-21 Santos Jose H Method for assessing risk of and predisposition to development of a pathology related to the presence of anti-epcr autoantibodies
EP1986568B1 (en) 2006-02-03 2017-04-05 Covidien LP Methods and devices for restoring blood flow within blocked vasculature
EP2403583B1 (en) 2009-03-06 2016-10-19 Lazarus Effect, Inc. Retrieval systems
US10207240B2 (en) 2009-11-03 2019-02-19 Gen9, Inc. Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly
US9260753B2 (en) 2011-03-24 2016-02-16 President And Fellows Of Harvard College Single cell nucleic acid detection and analysis
JP2017532024A (ja) 2014-09-09 2017-11-02 ザ・ブロード・インスティテュート・インコーポレイテッド コンポジット単一細胞核酸分析のための液滴ベースの方法および機器
WO2016130647A1 (en) 2015-02-11 2016-08-18 Lazarus Effect, Inc. Expandable tip medical devices and methods
CN107614700A (zh) 2015-03-11 2018-01-19 布罗德研究所有限公司 基因型和表型偶联
US11092607B2 (en) 2015-10-28 2021-08-17 The Board Institute, Inc. Multiplex analysis of single cell constituents
WO2017075297A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. High-throughput dynamic reagent delivery system
US11072816B2 (en) 2017-05-03 2021-07-27 The Broad Institute, Inc. Single-cell proteomic assay using aptamers

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2310133A2 (fr) * 1975-05-05 1976-12-03 Fabre Sa Pierre Nouveau medicament comportant un activateur du plasminogene perfectionne
US4447236A (en) * 1982-02-05 1984-05-08 Cordis Corporation Infusion catheter system
DE3330699A1 (de) * 1983-08-25 1985-03-07 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur gleichzeitigen bestimmung von fibrinogen und fibrinogen-spaltprodukten im plasma
US4610879A (en) 1984-01-06 1986-09-09 University Of Southern California Fibrinolytic enzyme from snake vernom
CA1237482A (en) * 1984-03-09 1988-05-31 Frank B. Stiles Catheter for effecting removal of obstructions from a biological duct
US4755167A (en) * 1984-04-10 1988-07-05 Research Corporation In vivo method for distribution and stirring of therapeutic agents
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4885242A (en) * 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4818700A (en) * 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) * 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5000185A (en) * 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
ZA889415B (en) 1987-12-18 1989-09-27 Chiron Corp Compositions and method for recombinant production of crotalidus venum fibrolase
WO1990007352A1 (en) 1989-01-04 1990-07-12 Boston Scientific Corporation Angioplasty catheter
US5222941A (en) * 1990-01-12 1993-06-29 Don Michael T Anthony Method of dissolving an obstruction in a vessel
ATE220721T1 (de) * 1990-01-16 2002-08-15 Ct Ingenieria Genetica Biotech Verfahren zur expression heterologischer gene in der hefe pichia pastoris, expressionsvektoren und transformierte mikroorganismen
US5709676A (en) * 1990-02-14 1998-01-20 Alt; Eckhard Synergistic treatment of stenosed blood vessels using shock waves and dissolving medication
US5250034A (en) * 1990-09-17 1993-10-05 E-Z-Em, Inc. Pressure responsive valve catheter
US5167628A (en) * 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5380273A (en) * 1992-05-19 1995-01-10 Dubrul; Will R. Vibrating catheter
EP0624642B1 (en) 1993-05-12 1999-01-20 Indian Council For Medical Research Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament
US5370653A (en) * 1993-07-22 1994-12-06 Micro Therapeutics, Inc. Thrombectomy method and apparatus
ATE249234T1 (de) 1993-12-17 2003-09-15 Mochida Pharm Co Ltd Lösliches thrombomodulin enthaltende zubereitung
US5626564A (en) * 1995-03-31 1997-05-06 Creighton University Adjustable sideholes catheter
US5830468A (en) * 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
ATE302599T1 (de) * 1996-05-24 2005-09-15 Angiotech Pharm Inc Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US5951981A (en) * 1996-12-02 1999-09-14 Diatide, Inc. Thrombolytic agents with antithrombotic activity
US6413760B1 (en) * 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
EP1037969A4 (en) * 1997-12-09 2003-05-21 Bristol Myers Squibb Co FIBRINOGEN CONVERSING ENZYME HYBRID
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6261820B1 (en) 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6455269B1 (en) * 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
AU2001281081A1 (en) 2000-08-03 2002-02-18 Zymogenetics Inc. Disintegrin homologs, zsnk10, zsnk11, and zsnk12

Also Published As

Publication number Publication date
KR20060114034A (ko) 2006-11-03
HK1049351A1 (en) 2003-05-09
SK4232002A3 (en) 2003-09-11
AU767827B2 (en) 2003-11-27
YU59604A (sh) 2005-11-28
JP2003511034A (ja) 2003-03-25
ZA200202206B (en) 2002-12-24
EA005944B1 (ru) 2005-08-25
MXPA02003126A (es) 2002-09-30
KR20020047208A (ko) 2002-06-21
CN101230340A (zh) 2008-07-30
SG127720A1 (en) 2006-12-29
US6617145B2 (en) 2003-09-09
EA006487B1 (ru) 2005-12-29
CA2386185A1 (en) 2001-04-12
CZ298502B6 (cs) 2007-10-24
KR100700753B1 (ko) 2007-03-28
EP1605049A3 (en) 2006-12-13
ES2240167T3 (es) 2005-10-16
DK1224298T3 (da) 2005-05-30
US20030186422A1 (en) 2003-10-02
ATE292180T1 (de) 2005-04-15
US6261820B1 (en) 2001-07-17
PL355017A1 (en) 2004-03-22
KR100711312B1 (ko) 2007-04-27
IL148787A0 (en) 2002-09-12
EP1224298A1 (en) 2002-07-24
PT1224298E (pt) 2005-06-30
HUP0202650A3 (en) 2005-01-28
NO20021501L (no) 2002-05-31
CZ20021034A3 (cs) 2003-06-18
CN100357430C (zh) 2007-12-26
HK1049351B (zh) 2005-07-29
NZ517951A (en) 2004-02-27
CN1402788A (zh) 2003-03-12
BR0014414A (pt) 2002-06-11
HUP0202650A2 (hu) 2002-12-28
EA200400290A1 (ru) 2005-02-24
RS20060033A (sr) 2006-12-15
DE60019147T2 (de) 2006-05-11
US20080058256A1 (en) 2008-03-06
US7195903B2 (en) 2007-03-27
EA200200410A1 (ru) 2002-10-31
NO20021501D0 (no) 2002-03-26
WO2001025445A1 (en) 2001-04-12
EP1605049A2 (en) 2005-12-14
DE60019147D1 (en) 2005-05-04
BG106577A (bg) 2003-04-30
EP1224298B1 (en) 2005-03-30
AU7625400A (en) 2001-05-10
US20020058322A1 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
YU22502A (sh) Fibrinolitički aktivni polipeptid
PT1232254E (pt) Processo para a produção de uma composição de plasmina acidificada reversivelmente inactiva
NO910811D0 (no) Vevsplasminogen-aktivator med zymogeniske- eller fibrinspesifikke egenskaper.
ATE239084T1 (de) Mutanten der pro-urokinase
AU7951798A (en) Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
ZA927360B (en) Improved tissue glue prepared by using cryoprecipitate
WO1988005081A3 (en) Novel plasminogen activator
HU9402063D0 (en) Bifunctional urocinase-variants having improved fibrinolytic properties and thrombin-inhibiting activity
AU2353688A (en) Modified tissue plasminogen activator
ES2067326T3 (es) Variante especifica de activador de plasminogeno tisular.
Rudenskaya et al. Studying in vitro fibrinolytic and thrombolytic properties of thiol-dependent serine proteinase from Thermoactinomyces vulgaris.